WNT5A and B-cell chronic lymphocytic leukemia: However, pre-treatment with zilovertamab, an anti-ROR1 antibody, inhibited the capacity of Wnt5a to induce ROR1Pos CLL cells to increase MMP-9, suggesting that this effect was mediated via ROR1-signaling (Fig. 2C).